No Compelling Evidence of Pancreatic Cancer Risk With GLP-1s No Compelling Evidence of Pancreatic Cancer Risk With GLP-1s
Up to 7 years treatment with GLP-1 receptor agonist in patients with type 2 diabetes didn ' t seem to increase pancreatic cancer risk in a large population-based cohort study.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Gastroenterology Source Type: news
More News: Cancer | Cancer & Oncology | Diabetes | Diabetes Type 2 | Endocrinology | Gastroenterology | Hematology | Pancreas | Pancreatic Cancer | Study